Genelux begins dosing in Phase II ovarian cancer trial
US-based oncolytic immunotherapy developer Genelux has started dosing patients in a Phase II clinical trial (VIRO-15) of its clinical-stage candidate GL-ONC1 to treat recurrent ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: MediciNova, Confo Therapeutics, Intra-Cellular Therapies
US-based biopharmaceutical company MediciNova plans to raise up to $200m by issuing securities on occasion. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: Ardena Group, Sumitomo Chemical
Belgian contract development and manufacturing organisation Ardena Group has completed the acquisition of Netherlands-based bioanalytical contract laboratory services provider Analytical Biochemical Laboratory. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news
Preclinical Oncology Models for Testing Immunotherapies
4T1 is a triple-negative mouse breast cancer cell line. Pharmatest utilises a 4T1 cell line with stable expression of green fluorescent protein (GFP) enabling easy and efficient detection of whole-body tumour burden. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news
Aduro Biotech starts dosing in Phase Ib combination trial for oncology
Aduro Biotech has started dosing patients in a Phase Ib clinical trial of its drug candidate ADU-S100 (MIW815) in combination with Novartis ’ PDR001 to treat advanced / metastatic solid tumours or lymphomas. (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news
BioLineRx launches Phase Ib/II combination trial for acute myeloid leukaemia
Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech ’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news
Axovant ’s Phase III trial of Alzheimer's disease drug fails to meet primary endpoints
Axovant Sciences has reported negative top-line results from its Phase III MINDSET clinical trial of intepirdine conducted to treat mild-to-moderate Alzheimer's disease (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news
US and UK researchers launch trial to study treatment approaches for multiple sclerosis
Researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, UK, have collaborated with a team from the Cleveland Clinic in Ohio, US, for a clinical trial for the treatment of multiple sclerosis (MS). (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news
Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news
AstraZeneca reports positive data from Phase III trial of Bevespi Aerosphere
AstraZeneca has reported positive top-line results from the Phase III PINNACLE 4 clinical trial of Bevespi Aerosphere to treat moderate to very severe chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news
argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris
Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV). (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news
Prometic to conduct PBI-4050 ’s Phase II/III trial for IPF in US
Canada-based Prometic Life Sciences has secured investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to evaluate its drug candidate PBI-4050 in a Phase II/III clinical trial to treat idiopathic pulmonary fibrosis (IP … (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news
Daiichi Sankyo studies esaxerenone in Phase III trial for diabetic nephropathy
Japanese pharmaceutical firm Daiichi Sankyo has started a Phase III clinical trial (ESAX-DN) of its product candidate esaxerenone to treat diabetic nephropathy in the country. (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news
Auris Medical concludes enrolment in Phase III trial of Keyzilen for tinnitus
Swiss biopharmaceutical firm Auris Medical has concluded patient enrolment in a Phase III clinical trial (TACTT3) of its product candidate Keyzilen to treat acute and post-acute inner ear tinnitus. (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news
Allergan reports positive Phase IIb two-year data from liver fibrosis trial
Allergan has reported positive top-line two-year results from its Phase IIb CENTAUR clinical trial of Cenicriviroc (CVC) to treat liver fibrosis in adults suffering from non-alcoholic steatohepatitis (NASH). (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2017 Category: Pharmaceuticals Source Type: news
